Liposome encapsulated prednisolone

Drug Profile

Liposome encapsulated prednisolone

Alternative Names: GLPG-0303; Liposomal prednisolone; Nanocort; PEG-liposomal prednisolone sodium phosphate

Latest Information Update: 28 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enceladus Pharmaceuticals
  • Developer Enceladus Pharmaceuticals; Galapagos NV; Leiden University Medical Center; Sun Pharmaceutical Industries
  • Class Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Corticosteroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Glucagon receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • Phase II Arteriovenous fistula; Graves ophthalmopathy; Ulcerative colitis
  • Suspended Multiple sclerosis

Most Recent Events

  • 20 Jul 2017 Phase-II clinical trials in Graves ophthalmopathy in Netherlands (IV) (EudraCT2017-001158-33)
  • 16 Mar 2016 Efficacy and adverse events data from a phase II trial in Ulcerative colitis released by Enceladus Pharmaceuticals
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top